OBJECTIVE: To probe into the clinical efficacy of compound Kushen injection combined with sodium ibandronate in the treatment of multiple myeloma bone pain. METHODS: Totally 80 patients newly diagnosed with multiple myeloma admitted into the Affiliated Hospital of North China University of Science and Technology from Oct. 2018 to Oct. 2020 were selected and divided into treatment group（40 cases） and control group（40 cases） via random number table. All the patients were treated with bortezomib combined with lenalidomide and dexamethasone. On that basis

the control group was given sodium ibandronate

while the treatment group was given compound Kushen injection combined with sodium ibandronate. The short-term efficacy

pain score

KPS score

serum serum alkaline phosphatase（ALP） level and incidences of adverse drug reactions were compared between two groups. RESULTS: The total remission rate of treatment group was 95.0%（38/40）

significantly higher than that of the control group（80.0%

32/40）

with statistically significant difference（P<0.05）. After treatment

the KPS scores were significantly improved

the pain scores and ALP levels were significantly decreased both groups

while the KPS score

pain score and ALP level were better in the treatment group than in the control group

with statistically significant differences（P<0.05）. The incidences of adverse drug reactions of the treatment group was 25.0%（10/40）

lower than 37.5%（15/40） of the control group

the difference was not statistically significant（P>0.05）. CONCLUSIONS: Compound Kushen injection combined with sodium ibandronate can treat multiple myeloma

which can effectively relieve patients’ bone pain

improve clinical efficacy and life quality.